FOXO Technologies Completes Acquisition of Vector Biosource
FOXO Technologies Inc. (OTCID: FOXO) has recently announced the successful closing of its acquisition of Vector Biosource Inc. This strategic move is poised to enhance FOXO's portfolio significantly as Vector is known for its capabilities in biospecimen sourcing and data provision for the biotechnology, clinical research, and pharmaceutical industries.
Details of the Acquisition
The acquisition involved a comprehensive purchase price, including a cash component of $500,000, and the issuance of 60,000 shares of Series E Cumulative Redeemable Secured Preferred Stock valued at $1.5 million. Additionally, FOXO has provided warrants allowing for the purchase of $2 million in common stock at a 10% premium relative to the stock’s closing price prior to the acquisition.
Growth Potential for Vector
Vector is already on a strong revenue trajectory, having reported approximately $225,000 in net revenues for the second quarter, which translates to a run rate of $0.9 million annually. With the backing of FOXO Technologies, there is an optimistic outlook for accelerated growth. Frank Dias, Jr., CEO of Vector, expressed enthusiasm about the partnership, stating that it will help propel their ambitious growth plans.
FOXO Technologies' Vision
As a dynamic player in the health and biotechnology sector, FOXO Technologies operates three core subsidiaries: Rennova Community Health, Myrtle Recovery Centers, and FOXO Labs. Each of these entities serves distinct purposes within the healthcare landscape, focusing on improving human health and expanding access to medical services.
Rennova Community Health
Rennova is at the helm of Scott County Community Hospital, which is designated as a critical access hospital. This facility plays a vital role in providing healthcare services to underserved communities in East Tennessee.
Myrtle Recovery Centers
Myrtle Recovery Centers are pivotal in offering behavioral health services, featuring a 30-bed facility that provides comprehensive inpatient and outpatient care for individuals seeking recovery from substance use disorders.
FOXO Labs and Innovative Solutions
FOXO Labs is dedicated to harnessing advanced technology to enhance human health and longevity. The focus is on innovation within various industries, propelling the development of groundbreaking products and solutions tailored to improve life quality.
Looking Ahead
The integration of Vector Biosource into FOXO is expected to broaden the company’s capabilities and market reach, particularly as the healthcare sector continues to evolve. With significant investments planned for scaling Vector’s operations, the collaborations between the companies are anticipated to foster exciting advancements and outcomes in health research.
Frequently Asked Questions
What is the significance of FOXO's acquisition of Vector Biosource?
The acquisition enhances FOXO's capabilities in biospecimen sourcing and data provision, thereby strengthening its position in the biotechnology and research sectors.
How much did FOXO Technologies pay for Vector Biosource?
The total purchase price included $500,000 in cash and additional transactions involving shares and warrants valued up to several million dollars based on performance metrics.
What are Vector Biosource’s primary services?
Vector provides sourcing of information, data, and biospecimens, primarily targeting the biotechnology and pharmaceutical research markets.
Who is the CEO of FOXO Technologies?
Seamus Lagan is the Chief Executive Officer of FOXO Technologies, leading the company's strategic initiatives and operations.
Where can I find more information about FOXO Technologies?
For additional details, you can visit the official website of FOXO Technologies to learn more about their services and initiatives.
